Why Is Microbot Medical a Speculative Robotics Bet Under $1

Microbot Medical trades under $1 because clinical approval remains unproven and revenue is minimal while cash burn continues relentlessly.

Microbot Medical trades under $1 because clinical approval remains unproven and revenue is minimal while cash burn continues relentlessly.

Richtech Robotics' stock surge reflects real partnerships and product demonstrations, not speculation—though valuation multiples suggest flawless execution ahead.

FDA approval and a European acquisition position this $226 million cardiac robotics maker for potential re-rating from penny stock valuations.

Richtech Robotics trades at $2.25 with $513M market cap—but could reach $8.27 by 2026 if it pulls off NVIDIA-like dominance in restaurant automation.

SERV's autonomous delivery robots compete on cost and flexibility, not the platform scale that made Uber dominant.

Autonomous policing robots show promise for niche tasks, but institutional and technical barriers block KSCP from dominating the market like Google did search.

Is Ondas Holdings (NASDAQ: ONDS) the next Raytheon of drone robotics? The honest answer is: not yet, and probably not in the way the comparison implies —...

Kraken Robotics, which trades over the counter in the United States under the ticker KRKNF, has earned the "next Palantir" comparison for one reason: it...

AeroVironment is building the kind of specialized dominance in tactical robotics and unmanned systems that Lockheed Martin commands across broader defense...

John Deere isn't the next Tesla of farming robotics—it's arguably already there, having captured the space with three decades of agricultural dominance...